© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Black women, as well as those with Medicaid or no insurance, were less likely to receive surgery and more likely to die.
The decision to sign up for a clinical trial is not easy; there are risks for everything we do in terms of health and wellness.
Recent studies have shown that the disease has a unique biology—different from that of more common forms of breast cancer
Study shows six months of trastuzumab works as well as a full year.
Abemaciclib approved for first-line treatment of HR-positive, HER2-negative breast cancer that has spread.
Adding Perjeta to adjuvant therapy reduces risk of post-surgery breast cancer recurrence.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
